197 related articles for article (PubMed ID: 16309315)
1. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
López-Lázaro M; Pastor N; Azrak SS; Ayuso MJ; Austin CA; Cortés F
J Nat Prod; 2005 Nov; 68(11):1642-5. PubMed ID: 16309315
[TBL] [Abstract][Full Text] [Related]
2. Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
López-Lázaro M; Pastor N; Azrak SS; Ayuso MJ; Cortés F; Austin CA
Leuk Res; 2006 Jul; 30(7):895-8. PubMed ID: 16387358
[TBL] [Abstract][Full Text] [Related]
3. Cardiac glycosides in cancer research and cancer therapy.
Winnicka K; Bielawski K; Bielawska A
Acta Pol Pharm; 2006; 63(2):109-15. PubMed ID: 17514873
[TBL] [Abstract][Full Text] [Related]
4. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
5. Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor.
Juang HH; Lin YF; Chang PL; Tsui KH
J Urol; 2010 Nov; 184(5):2158-64. PubMed ID: 20850842
[TBL] [Abstract][Full Text] [Related]
6. The dynamics of cell proliferation.
Moxnes JF; Haux J; Hausken K
Med Hypotheses; 2004; 62(4):556-63. PubMed ID: 15050107
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells.
Johansson S; Lindholm P; Gullbo J; Larsson R; Bohlin L; Claeson P
Anticancer Drugs; 2001 Jun; 12(5):475-83. PubMed ID: 11395576
[TBL] [Abstract][Full Text] [Related]
8. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
10. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
11. Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis.
Ramirez-Ortega M; Maldonado-Lagunas V; Melendez-Zajgla J; Carrillo-Hernandez JF; Pastelín-Hernandez G; Picazo-Picazo O; Ceballos-Reyes G
Eur J Pharmacol; 2006 Mar; 534(1-3):71-6. PubMed ID: 16507306
[TBL] [Abstract][Full Text] [Related]
12. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
13. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
14. Antitumor agents. Part 227: Studies on novel 4'-O-demethyl-epipodophyllotoxins as antitumor agents targeting topoisomerase II.
Xiao Z; Bastow KF; Vance JR; Lee KH
Bioorg Med Chem; 2004 Jun; 12(12):3339-44. PubMed ID: 15158802
[TBL] [Abstract][Full Text] [Related]
15. Cells lacking DNA topoisomerase II beta are resistant to genistein.
López-Lazaro M; Willmore E; Austin CA
J Nat Prod; 2007 May; 70(5):763-7. PubMed ID: 17411092
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy.
Kuhlmann J
Arzneimittelforschung; 1982; 32(6):698-704. PubMed ID: 6889430
[TBL] [Abstract][Full Text] [Related]
17. Digitoxin is a potential anticancer agent for several types of cancer.
Haux J
Med Hypotheses; 1999 Dec; 53(6):543-8. PubMed ID: 10687899
[TBL] [Abstract][Full Text] [Related]
18. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new xanthone analogues and their biological activity test--cytotoxicity, topoisomerase II inhibition, and DNA cross-linking study.
Woo S; Jung J; Lee C; Kwon Y; Na Y
Bioorg Med Chem Lett; 2007 Mar; 17(5):1163-6. PubMed ID: 17194586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
